Profile data is unavailable for this security.
About the company
Biocytogen Pharmaceuticals Beijing Co Ltd is a China-based company mainly engaged in drug development business and preclinical research. The Company operates its business through five segments. The Gene-editing Services segment provides the customized gene-editing services based on animals as well as cells. The Pre-clinical Pharmacology and Efficacy Evaluation segment provides preclinical pharmacology services for the evaluation of drug efficacy and toxicity. The Animal Models Selling segment breeds and sells the animal models for the external and internal use. The Antibody Development segment utilises its antibody discovery platforms to identify antibodies which have the potential to become drug candidates. The Innovative Drugs Development segment is engaged in research and development of innovative drugs with a focus on oncology and autoimmune disease therapeutics.
- Revenue in HKD (TTM)1.35bn
- Net income in HKD149.55m
- Incorporated2009
- Employees1.31k
- LocationBiocytogen Pharmaceuticals (Beijing) Co LtdNo. 12Baocan South Street, Daxing DistrictBeijing 102629ChinaCHN
- Phone+86 1 056967601
- Fax+86 1 056967666
- Websitehttps://www.biocytogen.com.cn/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| InnoCare Pharma Ltd | 1.62bn | -260.29m | 22.86bn | 1.15k | -- | 5.64 | -- | 14.13 | -0.1508 | -0.1508 | 0.8855 | 3.78 | 0.1504 | 1.70 | 3.74 | 1,245,225.00 | -2.52 | -6.41 | -2.87 | -7.45 | 86.97 | 86.07 | -16.78 | -71.71 | 6.44 | -- | 0.1996 | -- | 36.68 | 281.63 | 30.20 | -- | 3.42 | -- |
| TransThera Sciences (Nanjing) Inc | 0.00 | -268.17m | 23.44bn | 121.00 | -- | 35.41 | -- | -- | -0.6757 | -0.6757 | 0.00 | 1.66 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 5.89 | -- | 0.0052 | -- | -100.00 | -- | 20.03 | -- | -- | -- |
| Genscript Biotech Corp | 4.31bn | 643.60m | 23.70bn | 5.77k | 35.66 | 0.685 | 40.54 | 5.50 | 0.304 | 11.42 | 2.01 | 15.83 | 0.1259 | 5.94 | 4.39 | 773,535.30 | 0.3949 | -9.75 | 0.4933 | -13.19 | 51.78 | 52.05 | 3.14 | -46.54 | 1.90 | 1.18 | 0.0471 | -- | 6.07 | 16.81 | -115.90 | -- | 5.78 | -- |
| Joinn Laboratories China Co Ltd | 1.89bn | 255.13m | 24.97bn | 2.65k | 93.42 | 2.94 | -- | 13.20 | 0.3405 | 0.3405 | 2.37 | 10.84 | 0.175 | 0.7843 | 6.03 | 629,011.80 | 2.36 | 6.60 | 2.72 | 7.92 | 24.63 | 41.87 | 13.47 | 25.98 | 3.06 | -- | 0.0039 | 23.59 | -15.07 | 25.85 | -81.34 | -16.89 | 16.27 | -19.46 |
| Dizal Pharmaceutical Co Ltd | 688.87m | -983.23m | 25.06bn | 852.00 | -- | 15.18 | -- | 36.38 | -2.01 | -2.01 | 1.40 | 3.14 | 0.2644 | 0.8102 | 5.84 | 713,322.50 | -37.97 | -46.55 | -55.30 | -56.24 | 95.12 | 90.63 | -143.64 | -825.75 | 2.42 | -111.09 | 0.4239 | -- | 294.24 | 54.40 | 23.63 | -- | 58.33 | -- |
| Wuhan Healthgen Biotechnology Corp | 26.51m | -182.27m | 28.45bn | 215.00 | -- | 50.51 | -- | 1,073.26 | -0.4498 | -0.4498 | 0.0654 | 1.39 | -- | -- | -- | 131,386.80 | -- | -- | -- | -- | 41.12 | -- | -687.60 | -- | 0.359 | -30.87 | 0.5497 | -- | 3.92 | -- | 19.04 | -- | -- | -- |
| Insilico Medicine Cayman TopCo | 418.31m | -346.05m | 29.52bn | -- | -- | -- | -- | 70.58 | -0.6208 | -0.6208 | 0.7505 | -9.54 | -- | -- | -- | -- | -- | -- | -- | -- | 83.56 | -- | -82.72 | -- | -- | -- | -- | -- | 67.71 | -- | 91.92 | -- | -- | -- |
| Biocytogen Phrmutcls (Beijing) Co Ltd | 1.35bn | 149.55m | 31.50bn | 1.31k | 120.46 | 17.89 | 101.67 | 23.39 | 0.3752 | 0.3752 | 3.38 | 2.53 | 0.4841 | 51.82 | 6.18 | 1,205,961.00 | 5.37 | -- | 6.84 | -- | 77.08 | -- | 11.10 | -- | 1.88 | 4.27 | 0.4065 | -- | 36.76 | -- | 108.76 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Lake Bleu Capital (Hong Kong) Ltd.as of 07 Jan 2026 | 5.62m | 5.07% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 197.50k | 0.18% |
| SSgA Funds Management, Inc.as of 05 Feb 2026 | 51.50k | 0.05% |
| DFA Australia Ltd.as of 30 Nov 2025 | 241.00 | 0.00% |
